Lytic Enzyme Composition for Intracellular Mycobacteria Envelope Disruption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments struggle to effectively target and penetrate the complex cell envelope of intracellular bacterial pathogens like mycobacteria, which are difficult to access due to their thick cell wall and hydrophobic mycolate layer, posing a challenge in treating infections within host cells.
Innovation Solution
A supramolecular structure comprising Lysin A, Lysin B, isoamylase, and α-amylase enzymes with specific amino acid sequence identities, formulated into lipid nanoparticles or micelles, is designed to target and disrupt the cell envelope of mycobacteria, enhancing treatment delivery to intracellular compartments.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-bacterial compositions are used, then the infection can be treated in vitro, but the treatment cannot be delivered to the correct subcellular location within host cells
Solution Approach 1:
The patent employs host cell components (such as antibodies, complement proteins, or cellular uptake mechanisms) as intermediaries to facilitate the delivery of lytic enzymes to the intracellular mycobacteria. The composition is designed to exploit existing host cell pathways for targeted delivery, avoiding the need for direct penetration through the bacterial cell envelope from the extracellular space.
Solution Approach 2:
The lytic enzymes are nested within a delivery vehicle that can be taken up by host cells, creating a nested structure where the enzymes are protected until they reach the intracellular compartment. This nested approach allows the treatment to be delivered inside the host cell where the mycobacteria reside, overcoming the barrier of delivering treatment to the correct subcellular location.
2Ease of operation
If treatment is delivered to intracellular compartments, then accessibility to subcellular location is improved, but the complex cell envelope of mycobacteria remains difficult to penetrate
Solution Approach 1:
The cell envelope degradation is achieved through segmentation of the bacterial cell wall into multiple layers, each targeted by specific lytic enzymes. The composition includes a cocktail of enzymes that sequentially or simultaneously degrade different components of the cell envelope (mycolic acids, arabinogalactan, peptidoglycan), effectively segmenting and dismantling the complex structure.
Solution Approach 2:
The patent uses a composite enzymatic system comprising multiple lytic enzymes with different specificities and mechanisms of action. This composite approach allows simultaneous attack on different layers of the cell envelope, with enzymes targeting mycolic acids, arabinogalactan, and peptidoglycan working together to compromise the integrity of the complex cell wall structure.
3Reliability
If a cocktail of lytic enzymes is used, then the ability to degrade complex cell envelope is improved, but the formulation and delivery complexity increases
Solution Approach 1:
Multiple lytic enzymes are merged into a single composition formulation that can be administered as one treatment. The enzymes are combined in a way that maintains their individual activities while simplifying delivery, potentially using protein carriers or lipid-based formulations that stabilize the enzyme mixture and facilitate co-delivery to the intracellular compartment.
Solution Approach 2:
The composition is designed with multi-functionality, where the same delivery vehicle or formulation platform serves multiple purposes: protecting the enzymes, facilitating cellular uptake, and enabling delivery to the correct intracellular compartment. This universal approach simplifies the overall system despite the complexity of the enzymatic cocktail.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively delivers lytic enzymes to intracellular mycobacteria, overcoming the barrier of the complex cell envelope and improving treatment efficacy by specifically targeting and disrupting bacterial cells within host cells.
Implementation Method 1
Lysin A and Lysin B are lytic proteins that have been shown to degrade mycobacterial cell envelopes. The composition includes one or more of a Lysin A, a Lysin B, an isoamylase, and an α-amylase.
Data Source
AI summary
The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells, residing within a host cell (e.g., a mammalian cell, e.g., immune cell, e.g., macrophage or dendritic cell). The compositions and methods include delivering a mixture of lytic enzymes to specifically target the cell envelope of a group of related bacterial species in the intracellular compartment (endosome, phagosome, lysosome, or cytosol) in which above mentioned orders of bacteria infect, grow, hide, and go quiescent.